Recruiting OBSERVATIONAL NCT07260110
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States (TEPLI-QUEST)
TEPLIzumab: QUality of Life Evaluation During Stage Transition
Sponsor: Sanofi
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Updated 1 time since 2026 Last updated: Nov 21, 2025 Started: Oct 31, 2025 Primary completion: Dec 3, 2030 Completion: Dec 3, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07260110, this observational or N/A phase trial focuses on Type 1 Diabetes and remains actively recruiting participants. Sponsored by Sanofi, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sanofi
Data source: Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .